Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
Zacks.com on MSN1d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseAmicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that two oral presentations and 20 ...
SG Americas Securities LLC cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 18.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor ...
Amicus Therapeutics announced that it will showcase two oral presentations and 20 posters related to its research on Fabry and Pompe diseases at the 21st Annual WORLDSymposium™ 2025 taking place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback